NCT02254239View on ClinicalTrials.gov

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 4, 2016

Primary Completion Date

December 12, 2018

Study Completion Date

December 12, 2018

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT02254239 - Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter